Fave Yohanna Tata

Mr. Fave Yohanna Tata

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 November 2024 in Future Pharmacology
Verified
Journal Article
Open access
PDF file
AMAGANZE GLOIRE-AIME MUSHEBENGE
AGANZE GLOIRE-AIME MUSHEBENGE
SUSamuel Chima Ugbaja
Samuel Chima Ugbaja
NMNonjabulo Ntombikhona Magwaza
Nonjabulo Ntombikhona Magwaza
NMNonkululeko Avril Magini
Nonkululeko Avril Magini
TMTambwe Willy Muzumbukilwa
Tambwe Willy Muzumbukilwa
HKHezekiel Kumalo
Hezekiel Kumalo
The main proteinase (Mpro), or 3CLpro, is a critical enzyme in the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) lifecycle and is responsible for breaking down and releasing vital functional viral proteins crucial for virus development and transmission. As a catalytically active dimer, its dimerization interface has become an attractive target for antiviral drug development. Recent research has extensively investigated the enzymatic activity of Mpro, focusing on its role in regulating the coronavirus replication complex and its significance in virus maturation and infectivity. Computational investigations have identified four druggable pockets, suggesting potential allosteric sites beyond the substrate-binding region. Empirical validation through site-directed alanine mutagenesis has targeted residues in both the active and allosteric regions and corroborated these predictions. Structural studies of drug target proteins can inform therapeutic approaches, with metadynamics simulations shedding light on the role of H163 in regulating Mpro function and providing insights into its dynamic equilibrium to the wild-type enzyme. Despite the efficacy of vaccines and drugs in mitigating SARS-CoV-2 spread, its ongoing viral evolution, selective pressures, and continued transmission pose challenges, potentially leading to resistant mutations. Phylogenetic analyses have indicated the existence of several resistant variations predating drug introduction to the human population, emphasizing the likelihood of drug spread. Hydrogen/deuterium-exchange mass spectrometry reveals the structural influence of the mutation. At the same time, clinical trials on 3CLPro inhibitors underscore the clinical significance of reduced enzymatic activity and offer avenues for future therapeutic exploration. Understanding the implications of 3CLPro mutations holds promise for shaping forthcoming therapeutic strategies against COVID-19. This review delves into factors influencing mutation rates and identifies areas warranting further investigation, providing a comprehensive overview of Mpro mutations, categorization, and terminology. Moreover, we examine their associations with clinical outcomes, illness severity, unresolved issues, and future research prospects, including their impact on vaccine efficacy and potential therapeutic targeting.

18 September 2025 in ChemistrySelect
Verified
Journal Article
Open access
FTFave Yohanna Tata
Fave Yohanna Tata
SUSamuel C. Ugbaja
Samuel C. Ugbaja
MNMthokozisi B. Nxumalo
Mthokozisi B. Nxumalo
AOAdeshina I. Odugbemi
Adeshina I. Odugbemi
HKHezekiel M. Kumalo
Hezekiel M. Kumalo
RKRene Khan
Rene Khan
Hyperglycaemia exacerbates tissue damage and complications in COVID‐19 and metabolic disorders. Flavonoids have shown diverse therapeutic potential in metabolic and infectious diseases, yet their molecular mechanisms remain unclear. The 5' adenosine monophosphate‐activated protein kinase (AMPK) is an energy sensor and a promising therapeutic target in diabetes and viral infections. This study investigated the binding affinity, structural stability and conformational dynamics of flavonoids with AMPK through molecular docking, molecular dynamics (MD) simulations (Maestro Schrodinger, Amber 18) carried out for 100 ns, and MM/GBSA binding free energy calculations. In vitro cytotoxicity and biochemical assays, including MTT, ATP, ΔΨm, CYP3A4, and LDH, were performed on HepG2 cells and analyzed using one‐way ANOVA with Tukey's post hoc test. Rutin showed the strongest binding to AMPK (−64.87 ± 10.07 kcal/mol), indicating superior binding and potential biological effects. Computational analysis identified key residues Glu86, Glu92, Glu135 and Asp149 involved in direct hydrogen bonding and electrostatic interactions, contributing to binding affinity and stability in the AMPK binding pocket. Rutin maintained nearly 100% cell viability up to 500 µM, significantly increased ATP and CYP3A4 levels while reducing LDH without impacting ΔΨm, indicating preserved mitochondrial integrity, enhanced metabolism and bioenergetics. These findings showed rutin as a safe and potent AMPK modulator with potential for further optimization and preclinical evaluations to treat diabetes and other diseases associated with mitochondrial dysfunction and metabolic stress.

8 June 2026 in Cell Biochemistry and Biophysics
Verified
Journal Article
Open access
FTFave Yohanna Tata
Fave Yohanna Tata
MNMthokozisi B. Nxumalo
Mthokozisi B. Nxumalo
VOVincent A. Obakachi
Vincent A. Obakachi
HKHezekiel M. Kumalo
Hezekiel M. Kumalo
RKRené B. Khan
René B. Khan
There has been a compelling need to identify new therapeutic targets and agents owing to the increasing complexity of disease mechanisms. Angiotensin-converting enzyme 2 (ACE2), the primary host receptor for severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2, plays a crucial role in the pathophysiology of COVID-19, making ACE2 a potential biological target. Identification of small molecules that can interact with ACE2 may offer insights into a host-targeted approach relevant to viral entry and ACE2-associated cellular pathways. The study evaluated allosteric interactions of selected flavonoids with ACE2, the cytotoxicity and metabolic effects of the promising candidate in A549 cells through computational and in vitro methods. Molecular docking identified flavonoid binding to ACE2, followed by a 120 ns molecular dynamics (MD) simulation to characterize the stability and dynamic behaviour of ACE2-flavonoid complexes. MM/GBSA binding free energy calculations and per residue energy decomposition were performed to identify key interactions stabilizing ligand binding. The in silico analyses showed ARG255, PRO328, GLU357, GLU384, GLU388, and ARG500 as the key allosteric residues contributing to ACE2-flavonoid complex stability. Rutin exhibited the most favourable binding affinity, followed by isoquercetin. Based on computational findings, rutin was selected for evaluation in A549 cells to assess cytotoxicity, metabolic and mitochondrial effects using MTT assay, ATP quantification, mitochondrial membrane potential (MMP), CYP3A4 activity and LDH release for membrane integrity. In vitro analyses showed that rutin is non-cytotoxic up to 500µM, enhances ATP production without adversely affecting MMP and membrane integrity. These findings indicate that rutin formed stable interactions with ACE2, with the potential to influence cellular energy metabolism without inducing cytotoxicity and therapeutic benefits in conditions linked to mitochondrial dysfunction and metabolic stress. While direct ACE2 enzymatic modulation was not confirmed experimentally, these findings provide a mechanistic basis for further studies on ACE2-flavonoid interactions and their potential biological implications in ACE2-associated diseases.

8 July 2024 in Preprints.org
Verified
Preprint
Open access
PDF file
AMAGANZE GLOIRE-AIME MUSHEBENGE
AGANZE GLOIRE-AIME MUSHEBENGE
SUSamuel Chima Ugbaja
Samuel Chima Ugbaja
NMNonjabulo Ntombikhona Magwaza
Nonjabulo Ntombikhona Magwaza
NMNonkululeko Avril Magini
Nonkululeko Avril Magini
TMTambwe Willy Muzumbukilwa
Tambwe Willy Muzumbukilwa
HKHezekiel Kumalo
Hezekiel Kumalo
The main proteinase (Mpro), or 3CLpro, is a critical enzyme in the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) lifecycle and is responsible for breaking down and releasing vital functional viral proteins crucial for virus development and transmission. As a catalytically active dimer, its dimerization interface has become an attractive target for antiviral drug development. Recent research has extensively investigated the enzymatic activity of Mpro, focusing on its role in regulating the coronavirus replication complex and its significance in virus maturation and infectivity. Computational investigations have identified four druggable pockets, suggesting potential allosteric sites beyond the substrate-binding region. Empirical validation through site-directed alanine mutagenesis targeted residues in both the active and allosteric regions corroborated these predictions. Structural studies of drug target proteins can inform therapeutic approaches, with metadynamics simulations shedding light on the role of H163 in regulating Mpro function and providing insights into its dynamic equilibrium to the wild-type enzyme. Despite the efficacy of vaccines and drugs in mitigating SARS-CoV-2 spread, ongoing viral evolution, selective pressures, and continued transmission pose challenges, potentially leading to resistance mutations. Phylogenetic analyses indicated the existence of several resistance variations predating drug introduction to the human population, emphasizing the likelihood of drug spread. Hydrogen/deuterium-exchange mass spectrometry reveals the structural influence of the mutation, while clinical trials on 3CLPro inhibitors underscore the clinical significance of reduced enzymatic activity and offer avenues for future therapeutic exploration. Understanding the implications of 3CLPro mutations holds promise for shaping forthcoming therapeutic strategies against COVID-19. This review delves into factors influencing mutation rates and identifies areas warranting further investigation, providing a comprehensive overview of Mpro mutations, their categorization, and terminology. Moreover, we examined their associations with clinical outcomes, illness severity, unresolved issues, and future research prospects, including their impact on vaccine efficacy and potential therapeutic targeting.

Verified
Journal Article
Open access
PDF file
FTFave Yohanna Tata
Fave Yohanna Tata
MNMthokozisi Bongani Nxumalo
Mthokozisi Bongani Nxumalo
NNNosipho Ntanzi
Nosipho Ntanzi
AMAganze Gloire-Aimé Mushebenge
Aganze Gloire-Aimé Mushebenge
RKRene R. Khan
Rene R. Khan
HKHezekiel Kumalo
Hezekiel Kumalo
The convergence of metabolic dysfunction and infectious diseases has become increasingly evident, particularly during the COVID-19 pandemic. AMP-activated protein kinase (AMPK) and angiotensin-converting enzyme 2 (ACE2) emerge as pivotal molecular regulators linking metabolic homeostasis, endothelial integrity, immune modulation, and viral pathogenesis. Metabolic diseases such as diabetes, obesity, and non-alcoholic fatty liver disease are marked by insulin resistance, chronic inflammation, oxidative stress, and endothelial dysfunction, collectively increasing susceptibility to severe viral infections and outcomes. This review examines experimental, computational, and translational evidence exploring the interplay between AMPK and ACE2, focusing on metabolic, vascular, and inflammatory pathways relevant to viral infections. Recent findings show a bidirectional functional relationship between AMPK and ACE2, where AMPK phosphorylation supports ACE2 expression and function, and ACE2 signaling reciprocally enhances AMPK activity, forming a protective metabolic–vascular loop. Disruption of this axis, particularly through SARS-CoV-2-induced ACE2 degradation, exacerbates metabolic deterioration, vascular damage, and exaggerated inflammatory responses. Preclinical and in silico studies show that pharmacological AMPK activators, including metformin and bioactive flavonoids, demonstrate pleiotropic metabolic, anti-inflammatory, endothelial protective, and potential antiviral activities, hinting at the therapeutic potential of modulating the AMPK-ACE2 axis, despite the limited clinical application of flavonoids. The AMPK-ACE2 axis represents an important molecular link between metabolic regulation, renovascular health, and immune defense mechanisms. This evaluation connects AMPK and ACE2 from isolated signaling nodes into a coordinated pharmacological axis with implications for interventions in cardiometabolic and viral diseases. Future research should prioritize mechanistic validation and conduct integrated experimental and clinical investigations to establish AMPK-ACE2 co-targeting as a viable therapeutic strategy for mitigating cardiometabolic disease burden and enhancing resilience against viral infections.